Global Oligonucleotide Contract Manufacturing Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Oligonucleotide Contract Manufacturing Market Overview

The Oligonucleotide Contract Manufacturing Market was valued at USD 2.18 billion in 2025 and is projected to reach USD 6.80 billion by 2033, growing at a CAGR of 15.30% from 2026 to 2033. The Oligonucleotide Contract Manufacturing Market is experiencing consistent growth driven by increasing demand for outsourced nucleic acid manufacturing services, rising adoption of oligonucleotide-based therapeutics, advancements in synthesis and purification technologies, and expanding applications across drug discovery, gene therapy, molecular diagnostics, and personalized medicine.

The growing development of antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and other RNA-based therapies, combined with increasing investments in biotechnology research and precision medicine, is encouraging pharmaceutical and biotechnology companies to collaborate with specialized contract manufacturing organizations (CMOs). Advanced manufacturing platforms, improved scalability, and enhanced quality control processes are enabling efficient production of complex oligonucleotide molecules. In addition, increasing clinical trial activities, rising demand for customized oligonucleotide solutions, and growing outsourcing trends among emerging biotech companies are accelerating adoption of contract manufacturing services globally.

Key Market Trends & Insights

• North America dominated the Oligonucleotide Contract Manufacturing Market with the largest revenue share of 38.2% in 2025, supported by the presence of leading CDMO companies, advanced biotechnology infrastructure, strong investment in nucleic acid-based therapeutics, and growing demand for outsourced manufacturing services from pharmaceutical and biotechnology firms. The region benefits from established capabilities in GMP-compliant oligonucleotide production, advanced purification technologies, and large-scale synthesis platforms for therapeutic applications such as antisense oligonucleotides (ASOs) and small interfering RNA (siRNA). Increasing adoption of precision medicine, expansion of clinical pipelines for rare diseases, and rising commercialization of RNA-based therapies continue to strengthen North America’s leading position in the global market.
• The therapeutic development segment dominated the market with a 45.3% share in 2025, supported by increasing demand for oligonucleotide-based therapies, growing adoption of precision medicine approaches, and rising outsourcing activities by pharmaceutical and biotechnology companies.
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 9.4% from 2026 to 2033, fueled by increasing biotechnology investments, expanding pharmaceutical manufacturing capabilities, rising clinical research activities, and growing adoption of advanced nucleic acid-based therapies across China, Japan, India, and South Korea. The region is witnessing increased demand for outsourced oligonucleotide production due to cost advantages, improving GMP manufacturing infrastructure, and government initiatives supporting biotechnology innovation. In addition, the growing presence of emerging biotech companies and increasing focus on precision medicine are accelerating regional market growth.
• The therapeutic development segment dominates the application category with a 45.3% revenue share in 2025, supported by rising demand for oligonucleotide-based medicines targeting genetic disorders, oncology, cardiovascular diseases, and rare diseases. Pharmaceutical companies are increasingly outsourcing oligonucleotide synthesis and manufacturing to specialized CDMOs to reduce development timelines, manage production complexity, and access advanced manufacturing technologies. The growth of RNA therapeutics and gene-targeting approaches is further increasing the requirement for reliable contract manufacturing partners.
• The RNA oligonucleotides segment is projected to be the fastest-growing product type, registering a CAGR of 10.2% from 2026 to 2033, driven by rapid growth in RNA-based therapeutics, increasing research activities in mRNA and RNA interference technologies, and expanding applications in vaccines, oncology, and genetic disorders. Improvements in RNA synthesis, purification methods, and scalable manufacturing processes are enabling broader adoption of RNA-based drug candidates. Increasing investment by biotechnology companies in RNA platforms is expected to further accelerate demand for specialized oligonucleotide CDMO services.
• The diagnostic applications segment is expected to witness strong growth, supported by increasing adoption of oligonucleotide-based molecular diagnostics, nucleic acid amplification technologies, and biomarker detection solutions. The rising demand for accurate disease detection, infectious disease testing, and personalized diagnostics is encouraging the use of custom oligonucleotide products in diagnostic workflows. Advancements in PCR-based testing, sequencing technologies, and molecular assay development are creating additional opportunities for contract manufacturers.

Market Size & Forecast

• Global Market Value (2025): USD 2.18 Billion
• Expected Market Value (2033): USD 6.80 Billion
• Forecast CAGR (2026–2033): 15.30%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia-Pacific

Report Scope and Oligonucleotide Contract Manufacturing Market Segmentation

Oligonucleotide Contract Manufacturing Market Trends

Trend: Expansion of Biopharmaceutical Development and Rising Outsourcing of Oligonucleotide Manufacturing

The Oligonucleotide Contract Manufacturing Market is witnessing strong growth due to increasing demand for outsourced manufacturing services from pharmaceutical and biotechnology companies developing advanced therapeutics, including antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and other nucleic acid-based therapies. The rising number of clinical trials involving oligonucleotide drugs is encouraging companies to collaborate with specialized contract manufacturers to access advanced synthesis technologies, purification capabilities, and regulatory expertise without investing heavily in in-house infrastructure. The growing adoption of precision medicine and gene-targeted therapies is further accelerating demand for high-quality oligonucleotide production. For instance, the increasing development of RNA-based treatments and genetic medicines has encouraged manufacturers to expand GMP-compliant oligonucleotide production capacity to support clinical and commercial-scale requirements. In addition, advancements in solid-phase synthesis, purification technologies, and analytical characterization are improving manufacturing efficiency and enabling faster development timelines for emerging therapeutics.

Oligonucleotide Contract Manufacturing Market Dynamics

Key Market Driver: Increasing Demand for RNA-Based Therapeutics and Gene-Targeted Medicines

The rising adoption of oligonucleotide-based therapies is a major growth driver for the Oligonucleotide Contract Manufacturing Market. Pharmaceutical and biotechnology companies are increasingly developing innovative treatments based on antisense oligonucleotides, siRNA, mRNA-related technologies, and other nucleic acid platforms for treating genetic disorders, oncology, neurological diseases, and rare diseases. The growing pipeline of RNA therapeutics is creating significant demand for specialized contract manufacturing organizations (CMOs) capable of providing scalable synthesis, purification, and quality testing services. For example, the approval and commercialization of RNA-based therapies such as siRNA medicines have encouraged investment in advanced oligonucleotide manufacturing capabilities. In addition, increasing outsourcing trends among emerging biotech companies, rising regulatory requirements, and the need for cost-efficient production are encouraging companies to partner with experienced contract manufacturers. Furthermore, improvements in automated synthesis platforms and analytical technologies are enhancing production capacity and supporting the expansion of the market.

Key Restraint/Challenge: High Manufacturing Complexity and Cost Associated with Oligonucleotide Production

A significant challenge in the Oligonucleotide Contract Manufacturing Market is the complexity and high cost involved in manufacturing advanced oligonucleotide products. Large-scale oligonucleotide production requires sophisticated synthesis equipment, specialized purification systems, advanced analytical testing, and strict compliance with Good Manufacturing Practice (GMP) standards. The manufacturing process involves multiple steps, including chemical synthesis, purification, impurity removal, and quality validation, which can increase production costs and operational complexity. Small and mid-sized biotechnology companies may face challenges in accessing large-scale manufacturing capacity due to high service costs and limited availability of specialized facilities. In addition, variations in regulatory requirements across different regions, supply chain challenges for raw materials, and the need for continuous investment in technology upgrades create additional barriers for contract manufacturers. Maintaining consistent product quality and scalability during commercial production remains a key challenge for industry participants.

Key Market Opportunity: Expansion of AI-Driven Manufacturing, Automation, and Personalized Medicine Applications

The integration of advanced automation, artificial intelligence (AI), and digital manufacturing technologies presents significant growth opportunities for the Oligonucleotide Contract Manufacturing Market. AI-based process optimization and automated manufacturing platforms are enabling improved production efficiency, reduced batch variability, and enhanced quality control during oligonucleotide synthesis. Digital monitoring systems and advanced analytics are helping manufacturers optimize reaction conditions, improve yield, and accelerate development timelines. In addition, the growing focus on personalized medicine and rare disease therapies is creating demand for customized oligonucleotide production services, including smaller batch manufacturing and patient-specific therapeutic development. Emerging markets across Asia-Pacific, particularly China, India, and South Korea, are presenting new opportunities due to expanding biotechnology sectors, increasing healthcare investments, and growing outsourcing activities. Furthermore, continued advancements in RNA therapeutics, gene-editing technologies, and next-generation drug delivery platforms are expected to strengthen demand for specialized oligonucleotide contract manufacturing services globally.

Oligonucleotide Contract Manufacturing Market Scope

The oligonucleotide contract manufacturing market is segmented on the basis of product type and application.

By Product Type

On the basis of product type, the Oligonucleotide Contract Manufacturing Market is segmented into DNA oligonucleotides, RNA oligonucleotides, antisense oligonucleotides (ASOs), Small Interfering RNA (siRNA), aptamers, and Other oligonucleotide products. The antisense oligonucleotides (ASOs) segment dominated the market with a 34.6% share in 2025, owing to increasing demand for targeted genetic therapies, rising development of treatments for rare genetic disorders, and growing adoption of antisense-based medicines. ASOs are widely used for regulating gene expression by targeting specific RNA sequences, creating significant demand among pharmaceutical and biotechnology companies developing precision medicine solutions. The increasing number of clinical trials focused on neurological disorders, genetic diseases, and oncology applications is further supporting outsourcing of ASO manufacturing to specialized CDMOs. In addition, advancements in solid-phase synthesis, purification technologies, and analytical characterization are improving manufacturing efficiency and scalability, reinforcing the leading position of the ASO segment in the global market.

The small interfering RNA (siRNA) segment is expected to witness the fastest growth at a CAGR of 10.2% from 2026 to 2033, driven by increasing investment in RNA interference (RNAi)-based therapeutics and growing demand for gene-silencing technologies. siRNA-based approaches are gaining importance in treating metabolic disorders, genetic diseases, and oncology indications due to their ability to selectively suppress disease-causing genes. The rising commercialization of RNA-based medicines and expanding clinical pipelines are encouraging pharmaceutical companies to collaborate with contract manufacturers for scalable siRNA production. Furthermore, improvements in conjugation technologies, lipid nanoparticle delivery systems, and advanced purification methods are accelerating adoption of siRNA manufacturing services globally.

By Application

On the basis of application, the Oligonucleotide Contract Manufacturing Market is segmented into therapeutic development, diagnostic applications, research & development, drug discovery, and other applications. The therapeutic development segment dominated the market with a 45.3% share in 2025, supported by increasing demand for oligonucleotide-based therapies, growing adoption of precision medicine approaches, and rising outsourcing activities by pharmaceutical and biotechnology companies. Oligonucleotides are increasingly being utilized in the development of treatments for rare diseases, neurological disorders, cancer, and genetic conditions, creating strong demand for specialized manufacturing capabilities. The growing pipeline of RNA therapeutics, antisense therapies, and gene-targeting medicines is encouraging companies to partner with CDMOs for GMP-compliant production, process optimization, and analytical testing. In addition, increasing regulatory approvals for nucleic acid-based therapies are strengthening market growth and expanding the role of contract manufacturers in therapeutic development.

The drug discovery segment is projected to register the fastest growth at a CAGR of 9.8% from 2026 to 2033, driven by increasing utilization of custom oligonucleotides in target validation, molecular research, biomarker identification, and early-stage therapeutic development. Pharmaceutical companies and research organizations are increasingly outsourcing oligonucleotide synthesis to accelerate discovery programs and reduce internal manufacturing complexity. The expansion of genomics research, next-generation sequencing applications, and personalized medicine initiatives is further increasing demand for high-quality oligonucleotide products. Moreover, advancements in automated synthesis platforms, high-throughput screening technologies, and molecular biology research tools are expected to create significant opportunities for contract manufacturing providers.

Oligonucleotide Contract Manufacturing Market Regional Analysis

North America dominated the Oligonucleotide Contract Manufacturing Market and accounted for the largest revenue share of 38.2% in 2025, supported by the presence of leading contract development and manufacturing organizations (CDMOs), advanced biotechnology infrastructure, strong pharmaceutical R&D capabilities, and increasing outsourcing of oligonucleotide production by biotech and pharmaceutical companies. The region benefits from well-established GMP-compliant manufacturing facilities, advanced solid-phase synthesis technologies, and extensive expertise in producing complex nucleic acid-based therapeutics, including antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and other RNA-based medicines. Increasing investments in precision medicine, rising clinical trials for genetic disorders, oncology, and rare diseases, and growing commercialization of RNA therapeutics are further strengthening North America’s leadership position in the Oligonucleotide Contract Manufacturing Market.

U.S. Oligonucleotide Contract Manufacturing Market Insight

The U.S. oligonucleotide contract manufacturing market is witnessing strong growth due to increasing demand for outsourced manufacturing solutions from pharmaceutical and biotechnology companies developing advanced nucleic acid-based therapies. The country’s strong biotechnology ecosystem, presence of major CDMO providers, and significant investments in RNA therapeutics and gene-targeted medicines are driving market expansion. Increasing adoption of antisense oligonucleotide therapies, siRNA-based treatments, and personalized medicine approaches is accelerating demand for scalable and high-quality manufacturing services. In addition, rising clinical development activities, FDA approvals of innovative RNA-based therapies, and increasing focus on reducing manufacturing timelines are encouraging companies to partner with specialized oligonucleotide contract manufacturers across the U.S.

Europe Oligonucleotide Contract Manufacturing Market Insight

The Europe oligonucleotide contract manufacturing market remains a significant contributor to global revenue, driven by strong pharmaceutical research capabilities, increasing biotechnology investments, and growing demand for outsourced production of advanced therapeutics. The region benefits from established healthcare infrastructure, strict regulatory standards, and increasing adoption of nucleic acid-based medicines for rare diseases, neurological disorders, and oncology applications. European pharmaceutical and biotechnology companies are increasingly collaborating with CDMOs to access specialized oligonucleotide synthesis, purification, and analytical testing capabilities. Furthermore, government support for biotechnology innovation and expanding research activities in gene therapies and precision medicine are supporting market growth across major European countries.

U.K. Oligonucleotide Contract Manufacturing Market Insight

The U.K. oligonucleotide contract manufacturing market is experiencing steady growth, supported by increasing biotechnology research activities, rising investment in advanced therapeutic development, and growing demand for outsourced manufacturing services. The country’s strong academic research ecosystem and expanding life sciences sector are contributing to the development of RNA-based therapies and genetic medicines. Increasing collaboration between biotechnology companies and contract manufacturers is driving demand for GMP-compliant oligonucleotide production capabilities. Furthermore, growing focus on personalized medicine, rare disease treatment, and advanced molecular therapies is positioning the U.K. as an important market for oligonucleotide contract manufacturing services.

Germany Oligonucleotide Contract Manufacturing Market Insight

The Germany oligonucleotide contract manufacturing market is expanding steadily due to the country’s strong pharmaceutical manufacturing base, advanced biotechnology research capabilities, and increasing investments in nucleic acid-based therapeutic development. German pharmaceutical companies and research organizations are increasingly utilizing contract manufacturing services for oligonucleotide synthesis, purification, and quality testing to support clinical and commercial-scale production. The country’s focus on innovation, regulatory compliance, and high-quality pharmaceutical manufacturing is supporting market expansion. In addition, growing demand for RNA therapeutics, precision medicine solutions, and advanced drug development platforms is further driving adoption of oligonucleotide contract manufacturing services in Germany.

Asia-Pacific Oligonucleotide Contract Manufacturing Market Insight

The Asia-Pacific oligonucleotide contract manufacturing market is expected to witness rapid growth and is projected to expand at a CAGR of 9.4% from 2026 to 2033, driven by increasing biotechnology investments, expanding pharmaceutical manufacturing capabilities, rising clinical research activities, and growing adoption of advanced nucleic acid-based therapies across China, India, Japan, and South Korea. The region is benefiting from cost-effective manufacturing advantages, improving GMP infrastructure, and increasing availability of specialized biotechnology services. Growing demand from emerging biotech companies for outsourced oligonucleotide production, combined with government initiatives supporting pharmaceutical innovation and life sciences development, is accelerating regional market growth.

Japan Oligonucleotide Contract Manufacturing Market Insight

The Japan oligonucleotide contract manufacturing market is witnessing consistent growth due to increasing investments in biotechnology research, advanced pharmaceutical manufacturing, and development of next-generation genetic medicines. Japanese pharmaceutical companies are increasingly focusing on RNA-based therapeutics, rare disease treatments, and precision medicine applications, creating demand for specialized oligonucleotide manufacturing services. The country’s strong research infrastructure, advanced healthcare system, and emphasis on innovative drug development are supporting market expansion. Furthermore, increasing collaborations between biotechnology firms and contract manufacturers are enhancing production capabilities and accelerating adoption of oligonucleotide-based therapies.

China Oligonucleotide Contract Manufacturing Market Insight

The China oligonucleotide contract manufacturing market is growing rapidly, driven by expanding biotechnology capabilities, increasing pharmaceutical R&D investments, and rising demand for advanced nucleic acid-based therapies. The country is witnessing significant growth in clinical research activities involving RNA therapeutics, gene-targeted medicines, and precision healthcare solutions. Increasing availability of GMP-certified manufacturing facilities, cost advantages, and government support for biotechnology innovation are encouraging domestic and international companies to utilize contract manufacturing services in China. Additionally, the growing presence of biotech startups and increasing focus on rare disease and oncology treatments are positioning China as one of the fastest-growing markets for Oligonucleotide Contract Manufacturing globally.

Oligonucleotide Contract Manufacturing Market Share

The Oligonucleotide Contract Manufacturing industry is primarily led by well-established companies, including:

• Thermo Fisher Scientific Inc. (U.S.)
• Merck KGaA (Germany)
• Agilent Technologies Inc. (U.S.)
• BioNTech SE (Germany)
• Danaher Corporation (U.S.)
• Eurofins Scientific SE (Luxembourg)
• Lonza Group AG (Switzerland)
• WuXi AppTec Co., Ltd. (China)
• TriLink BioTechnologies (U.S.)
• Kaneka Corporation (Japan)
• Nitto Denko Corporation (Japan)
• ST Pharm Co., Ltd. (South Korea)
• Azenta Life Sciences (U.S.)
• Maravai LifeSciences Holdings, Inc. (U.S.)
• GeneDesign Inc. (Japan)
• IDT (Integrated DNA Technologies) (U.S.)
• Biosearch Technologies (U.S.)
• Biosynth (Switzerland)
• Aptamer Group plc (U.K.)
• Nitto Avecia Pharma Services (U.S.)
• CordenPharma (Switzerland)
• Bachem Holding AG (Switzerland)
• PolyPeptide Group AG (Switzerland)
• Creative Biolabs (U.S.)
• GenScript Biotech Corporation (China)
• Synaffix B.V. (Netherlands)
• Sino Biological Inc. (China)
• Bio-Synthesis Inc. (U.S.)
• Microsynth AG (Switzerland)

Latest Developments in Oligonucleotide Contract Manufacturing Market

• In August 2023, EUROAPI announced the acquisition of BianoGMP, a specialized contract development and manufacturing organization (CDMO) focused on oligonucleotide development and manufacturing, to strengthen its position in the rapidly growing oligonucleotide market. The acquisition expanded EUROAPI’s capabilities across the oligonucleotide development lifecycle, including early-stage research, preclinical development, and commercial manufacturing support. The move reflected increasing demand from biotechnology and pharmaceutical companies for outsourced oligonucleotide manufacturing solutions, particularly for advanced modalities such as antisense oligonucleotides (ASOs) and RNA-based therapeutics
• In November 2023, EUROAPI completed the acquisition of BianoGMP, strengthening its CDMO expertise in the high-growth oligonucleotide segment. Following completion, BianoGMP became part of EUROAPI’s CDMO platform, enabling the company to offer broader oligonucleotide development and manufacturing services from research activities through commercialization. This development highlighted the growing trend of strategic acquisitions among CDMOs to expand capabilities in nucleic acid therapeutics and support increasing outsourcing demand from drug developers
• In October 2023, ST Pharm announced plans to expand its oligonucleotide manufacturing capabilities with the goal of becoming one of the world’s leading suppliers of oligonucleotide-based therapeutics. The South Korean CDMO highlighted ongoing development of its second manufacturing facility to increase production capacity for nucleic acid therapeutics, including oligonucleotides used in emerging RNA-based medicines. The expansion reflected rising global demand for scalable manufacturing capacity driven by growth in antisense oligonucleotide and small interfering RNA (siRNA) pipelines
• In March 2024, ST Pharm announced a major investment of approximately $110 million to expand oligonucleotide API manufacturing capacity at its Banwol site in South Korea. The new facility expansion was designed to support manufacturing of advanced oligonucleotide modalities, including antisense oligonucleotides (ASOs), siRNA, and CRISPR-related guide RNA products. This investment demonstrated the increasing focus of CDMOs on building large-scale manufacturing infrastructure to meet demand from biotechnology companies developing next-generation genetic medicines
• In November 2024, FUJIFILM Diosynth Biotechnologies announced the first phase of its global CDMO ecosystem expansion, strengthening its manufacturing network to support advanced therapies and pharmaceutical production. The expansion represented part of the company’s strategy to develop integrated manufacturing capabilities and increase global capacity for complex therapeutic products. The initiative reflects broader CDMO industry investment trends focused on expanding production capacity, improving supply chain resilience, and supporting outsourced manufacturing needs of innovative drug developers

SKU-76266